Loading…
Operates across two core business segments: Global Generics (GG), which includes branded and unbranded prescription medicine, OTC products, and biosimilars; and Pharmaceutical Services and Active Ingredients (PSAI), comprising APIs and custom pharmaceutical services. Also invests in future growth drivers like novel molecules, digital therapeutics, and consumer healthcare.
Strong presence in India with manufacturing facilities, R&D centers, headquarters, and significant sales operations. Active in community health and CSR initiatives.
Joint venture with Nestlé India to introduce health science nutraceutical products. Partnership with Sanofi to distribute vaccines portfolio in India. Launching trade generics.
Integrated global presence with operations including research, sales, and manufacturing across 76 countries worldwide.
Entered UK consumer health market with Histallay. Acquired global consumer healthcare brand Nicotinell (outside US). Aiming to reach 1.5 billion patients globally by 2030. Advance pipeline including biosimilars for global launches.
Regulatory approvals (e.g., USFDA), pricing policies in key markets, competitor actions (generic launches, pricing), success of R&D pipeline and strategic partnerships, geopolitical stability
Integrated value chain from API to finished dosages, strong footprint in key generic and emerging markets, focus on affordability and access, capabilities in complex product development (biosimilars, injectables), commitment to innovation and strategic collaborations
Detailed financial analysis and charts are coming soon!